The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Selective Cumulative Inhibition of Platelet Thromboxane Production by Low-dose Aspirin in Healthy Subjects
Open accessAbstract
Acetylation of platelet cyclooxygenase by oral aspirin is dose dependent and cumulative with repeated administration. However, no single dose of aspirin has been found to be completely selective of platelet thromboxane (TX) synthesis inhibition in man. We determined the dose dependence, cumulative nature and selectivity of aspirin effects on platelet TXB(2) and renal prostaglandin (PG) and prostacyclin (PGI(2)) production. We measured, by radioimmunoassay, serum TXB(2) levels after whole blood clotting and urinary excretion of PGE(2), PGF(2alpha), and 6-keto-PGF(1alpha), before and after single or repeated oral aspirin doses given to 46 healthy subjects. Single doses of 6-100 mg aspirin resulted in a linear (r = 0.92, P < 0.01) inhibition of platelet TXB(2) production, ranging from 12 to 95% after 24 h. A daily dose of 0.45 mg/kg given for 7 d produced a cumulative and virtually complete inhibition of platelet TXB(2) production, without significantly reducing the urinary excretion of PGE(2), PGF(2alpha), and 6-keto-PGF(1alpha) in both healthy men and women. The platelet inhibitory effect of this regimen was maintained unaltered throughout 1 mo of therapy, with no evidence of cumulative inhibition of renal PG-synthesis. Moreover, furosemide-induced renal PGI(2) synthesis and renin release were unaffected by chronic low-dose aspirin. Following cessation of aspirin therapy, platelet TXB(2) production returned toward control values at a similar rate as after a single higher dose. WE CONCLUDE THAT IN HEALTHY SUBJECTS: (a) aspirin causes a dose-dependent inhibition of platelet TXA(2) production, with no obvious sex-related difference; (b) the inhibitory effect of daily low-dose aspirin is cumulative on platelet TXA(2) but not on renal PG-synthesis; (c) during chronic low-dose aspirin therapy, renal PGI(2)-producing cells are readily activable by furosemide at a time of virtually complete suppression of platelet cyclooxygenase activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HABER, E., KOERNER, T., PAGE, L. B., KLIMAN, B., & PURNODE, A. (1969) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-29-10-1349 · Cited by 2,222
Acetylation of prostaglandin synthase by aspirin.
Roth, G. J., Stanford, N., & Majerus, P. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.8.3073 · Cited by 1,009
Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects
Patrono, C., Ciabattoni, G., Pinca, E., Pugliese, F., Castrucci, G., De Salvo, A., Satta, M. A., & Peskar, B. A. (1980) · Thrombosis Research · doi:10.1016/0049-3848(80)90066-3 · Cited by 651
Self-citationA Randomized, Controlled Trial of Aspirin in Persons Recovered From Myocardial Infarction
(1980) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1980.03300330019023 · Cited by 565
Inhibition of platelet prostaglandin synthetase by oral aspirin.
Burch, J. W., Stanford, N., & Majerus, P. W. (1978) · Journal of Clinical Investigation · doi:10.1172/jci108941 · Cited by 558
Urinary prostaglandins. Identification and origin.
Frölich, J. C., Wilson, T. W., Sweetman, B. J., Smigel, M., Nies, A. S., Carr, K., Watson, J. T., & Oates, J. A. (1975) · Journal of Clinical Investigation · doi:10.1172/jci107987 · Cited by 479
Prostacyclin is a circulating hormone
MONCADA, S., KORBUT, R., BUNTING, S., & VANE, J. R. (1978) · Nature · doi:10.1038/273767a0 · Cited by 379
Aspirin Prophylaxis of Venous Thromboembolism after Total Hip Replacement
Harris, W. H., Salzman, E. W., Athanasoulis, C. A., Waltman, A. C., & DeSanctis, R. W. (1977) · New England Journal of Medicine · doi:10.1056/nejm197712082972302 · Cited by 344
DIFFERENTIAL INHIBITION OF PROSTACYCLIN PRODUCTION AND PLATELET AGGREGATION BY ASPIRIN
Masotti, G., Poggesi, L., Galanti, G., Abbate, R., & Neri Serneri, G. G. (1979) · The Lancet · doi:10.1016/s0140-6736(79)92334-1 · Cited by 284
Estimated rate of prostacyclin secretion into the circulation of normal man.
FitzGerald, G. A., Brash, A. R., Falardeau, P., & Oates, J. A. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110373 · Cited by 269
Cited by
Thun, M. J., Henley, S. J., & Patrono, C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.252 · Cited by 1,433
Self-citationCyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., & FitzGerald, G. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003199 · Cited by 1,394
McAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,305
Low-Dose Aspirin for the Prevention of Atherothrombosis
Patrono, C., García Rodríguez, L. A., Landolfi, R., & Baigent, C. (2005) · New England Journal of Medicine · doi:10.1056/nejmra052717 · Cited by 1,218
Self-citationPlatelet Activation in Unstable Coronary Disease
Fitzgerald, D. J., Roy, L., Catella, F., & FitzGerald, G. A. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610163151602 · Cited by 1,141
Patrono, C., Coller, B., Dalen, J. E., Fitz Gerald, G. A., Fuster, V., Gent, M., Hirsh, J., & Roth, G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.39s · Cited by 963
Self-citationAspirin as an Antiplatelet Drug
Wood, A. J. J., & Patrono, C. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301808 · Cited by 955
Self-citationBerger, J. S., Roncaglioni, M. C., Avanzini, F., Pangrazzi, I., Tognoni, G., & Brown, D. L. (2006) · JAMA · doi:10.1001/jama.295.3.306 · Cited by 789
Patrono, C., Baigent, C., Hirsh, J., & Roth, G. (2008) · Chest · doi:10.1378/chest.08-0672 · Cited by 748
Self-citationAwtry, E. H., & Loscalzo, J. (2000) · Circulation · doi:10.1161/01.cir.101.10.1206 · Cited by 690
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects
Patrono, C., Coller, B., FitzGerald, G. A., Hirsh, J., & Roth, G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.234s · Cited by 671
Self-citationFitzGerald, G. A., Oates, J. A., Hawiger, J., Maas, R. L., Roberts, L. J., Lawson, J. A., & Brash, A. R. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110814 · Cited by 665
Thromboxane Biosynthesis and Platelet Function in Type II Diabetes Mellitus
Davì, G., Catalano, I., Averna, M., Notarbartolo, A., Strano, A., Ciabattoni, G., & Patrono, C. (1990) · New England Journal of Medicine · doi:10.1056/nejm199006213222503 · Cited by 597
Self-citationDose-Related Kinetics of Aspirin: Presystemic Acetylation of Platelet Cyclooxygenase
Pedersen, A. K., & FitzGerald, G. A. (1984) · New England Journal of Medicine · doi:10.1056/nejm198411083111902 · Cited by 558
The Salt Collaborative Group (1991) · The Lancet · doi:10.1016/0140-6736(91)92233-r · Cited by 553
Weitz, J. I., Eikelboom, J. W., & Samama, M. M. (2012) · Chest · doi:10.1378/chest.11-2294 · Cited by 527
Inflammation and the mechanism of action of anti‐inflammatory drugs
Vane, J., & Botting, R. (1987) · The FASEB Journal · doi:10.1096/fasebj.1.2.3111928 · Cited by 524
COX-2 and beyond: approaches to prostaglandin inhibition in human disease
FitzGerald, G. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1225 · Cited by 518
Effect of Dipyridamole and Aspirin on Late Vein-Graft Patency after Coronary Bypass Operations
Chesebro, J. H., Fuster, V., Elveback, L. R., Clements, I. P., Smith, H. C., Holmes, D. R., Bardsley, W. T., Pluth, J. R., Wallace, R. B., Puga, F. J., et al. (1984) · New England Journal of Medicine · doi:10.1056/nejm198401263100401 · Cited by 516
Hankey, G. J., & Eikelboom, J. W. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68040-9 · Cited by 505
Loll, P. J., Picot, D., & Garavito, R. M. (1995) · Nature Structural Biology · doi:10.1038/nsb0895-637 · Cited by 490
Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease.
FitzGerald, G. A., Pedersen, A. K., & Patrono, C. (1983) · Circulation · doi:10.1161/01.cir.67.6.1174 · Cited by 466
Self-citationClinical pharmacology of platelet cyclooxygenase inhibition.
Patrono, C., Ciabattoni, G., Patrignani, P., Pugliese, F., Filabozzi, P., Catella, F., Davì, G., & Forni, L. (1985) · Circulation · doi:10.1161/01.cir.72.6.1177 · Cited by 454
Self-citationWeksler, B. B., Pett, S. B., Alonso, D., Richter, R. C., Stelzer, P., Subramanian, V., Tack-Goldman, K., & Gay, W. A. (1983) · New England Journal of Medicine · doi:10.1056/nejm198304073081402 · Cited by 448
Aspirin Dose for the Prevention of Cardiovascular Disease: A Systematic Review
Campbell, C. L., Smyth, S., Montalescot, G., & Steinhubl, S. R. (2007) · JAMA · doi:10.1001/jama.297.18.2018 · Cited by 444
Clinical Implications of Prostaglandin and Thromboxane A2Formation
Oates, J. A., FitzGerald, G. A., Branch, R. A., Jackson, E. K., Knapp, H. R., & Roberts, L. J. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809223191206 · Cited by 444
Thromboxane A2: Physiology/pathophysiology, cellular signal transduction and pharmacology
Nakahata, N. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.01.001 · Cited by 443
Hsia, J., Hamilton, W. P., Kleiman, N., Roberts, R., Chaitman, B. R., & Ross, A. M. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011223232101 · Cited by 422
Reilly, I., & FitzGerald, G. (1987) · Blood · doi:10.1182/blood.v69.1.180.180 · Cited by 419
Gurbel, P. A., Bliden, K. P., DiChiara, J., Newcomer, J., Weng, W., Neerchal, N. K., Gesheff, T., Chaganti, S. K., Etherington, A., & Tantry, U. S. (2007) · Circulation · doi:10.1161/circulationaha.106.675587 · Cited by 417
Knapp, H. R., Reilly, I. A. G., Alessandrini, P., & FitzGerald, G. A. (1986) · New England Journal of Medicine · doi:10.1056/nejm198604103141501 · Cited by 415
Patrono, C. (2004) · European Heart Journal · doi:10.1016/j.ehj.2003.10.013 · Cited by 408
Self-citationClinical Implications of Prostaglandin and Thromboxane A2Formation
Oates, J. A., FitzGerald, G. A., Branch, R. A., Jackson, E. K., Knapp, H. R., & Roberts, L. J. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809153191106 · Cited by 379
Eikelboom, J. W., Hirsh, J., Spencer, F. A., Baglin, T. P., & Weitz, J. I. (2012) · Chest · doi:10.1378/chest.11-2293 · Cited by 379
Kozak, K. R., Crews, B. C., Morrow, J. D., Wang, L.-H., Ma, Y. H., Weinander, R., Jakobsson, P.-J., & Marnett, L. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206788200 · Cited by 368
Effects of Nonsteroidal Antiinflammatory Drugs on Platelet Function and Systemic Hemostasis
Schafer, A. I. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04050.x · Cited by 367
Patrono, C., Patrignani, P., & Rodríguez, L. A. G. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13418 · Cited by 364
Self-citationNarouze, S., Benzon, H. T., Provenzano, D. A., Buvanendran, A., De Andres, J., Deer, T. R., Rauck, R., & Huntoon, M. A. (2015) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000223 · Cited by 362
Mechanisms of platelet activation: Thromboxane A2 as an amplifying signal for other agonists
FitzGerald, G. A. (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90379-y · Cited by 353
Suppression of Thromboxane A2but Not of Systemic Prostacyclin by Controlled-Release Aspirin
Clarke, R. J., Mayo, G., Price, P., & FitzGerald, G. A. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110173251605 · Cited by 346
Benigni, A., Gregorini, G., Frusca, T., Chiabrando, C., Ballerini, S., Valcamonico, A., Orisio, S., Piccinelli, A., Pinciroli, V., Fanelli, R., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908103210604 · Cited by 326
IMPROVED AORTOCORONARY BYPASS PATENCY BY LOW-DOSE ASPIRIN (100 mg DAILY)
Lorenz, R. L., Weber, M., Kotzur, J., Theisen, K., Schacky, C. V., Meister, W., Reichardt, B., & Weber, P. C. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92446-2 · Cited by 320
Rocca, B., Secchiero, P., Ciabattoni, G., Ranelletti, F. O., Catani, L., Guidotti, L., Melloni, E., Maggiano, N., Zauli, G., & Patrono, C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.112202999 · Cited by 317
Self-citationThe first 3500 years of aspirin history from its roots – A concise summary
Montinari, M. R., Minelli, S., & De Caterina, R. (2019) · Vascular Pharmacology · doi:10.1016/j.vph.2018.10.008 · Cited by 315
Burla, B., Arita, M., Arita, M., Bendt, A. K., Cazenave-Gassiot, A., Dennis, E. A., Ekroos, K., Han, X., Ikeda, K., Liebisch, G., et al. (2018) · Journal of Lipid Research · doi:10.1194/jlr.s087163 · Cited by 312
García Rodríguez, L. A., Tacconelli, S., & Patrignani, P. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.041 · Cited by 305
Self-citationAspirin resistance: definition, mechanisms and clinical read-outs
Patrono, C. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00284.x · Cited by 299
Self-citationAspirin, Heparin, and Fibrinolytic Therapy in Suspected Acute Myocardial Infarction
Collins, R., Peto, R., Baigent, C., & Sleight, P. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703203361207 · Cited by 297
The clinical significance of inhibition of renal prostaglandin synthesis
Patrono, C., & Dunn, M. J. (1987) · Kidney International · doi:10.1038/ki.1987.164 · Cited by 296
Self-citationPharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects
Capone, M. L., Sciulli, M. G., Tacconelli, S., Grana, M., Ricciotti, E., Renda, G., Di Gregorio, P., Merciaro, G., & Patrignani, P. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.045 · Cited by 279
Self-citationA Prospective Study of Aspirin Use and Primary Prevention of Cardiovascular Disease in Women
Manson, J. E. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470040085027 · Cited by 272
Santilli, F., Rocca, B., De Cristofaro, R., Lattanzio, S., Pietrangelo, L., Habib, A., Pettinella, C., Recchiuti, A., Ferrante, E., Ciabattoni, G., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.047 · Cited by 265
Self-citationPatrignani, P., & Patrono, C. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.05.083 · Cited by 257
Self-citationROCCA, B., SANTILLI, F., PITOCCO, D., MUCCI, L., PETRUCCI, G., VITACOLONNA, E., LATTANZIO, S., MATTOSCIO, D., ZACCARDI, F., LIANI, R., et al. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04723.x · Cited by 256
Self-citationDavı̀, G., Gresele, P., Violi, F., Basili, S., Catalano, M., Giammarresi, C., Volpato, R., Nenci, G. G., Ciabattoni, G., & Patrono, C. (1997) · Circulation · doi:10.1161/01.cir.96.1.69 · Cited by 223
Self-citationLaekeman, G. M., van Hoof, L., Haemers, A., Berghe, D. A. V., Herman, A. G., & Vlietinck, A. J. (1990) · Phytotherapy Research · doi:10.1002/ptr.2650040304 · Cited by 89
He, L., Wickremasingha, P., Lee, J., Tao, B., Mendell-Harary, J., Walker, J., & Wight, D. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.12.033 · Cited by 25
Metadata
- Authors
- Patrignani, P., Filabozzi, P., & Patrono, C.
- Venue
- Journal of Clinical Investigation
- Published
- 1982-06-01
- Volume
- 69
- Issue
- 6
- Pages
- 1366-1372
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2125389594
- Cited by
- 937
- References
- 15
- FWCI
- 27.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.